A Biosimilar Drug for Treating Rheumatoid Arthritis and Ankylosing Spondylitis Begins Phase 3 Trials
source: pixabay.com

A Biosimilar Drug for Treating Rheumatoid Arthritis and Ankylosing Spondylitis Begins Phase 3 Trials

According to a story from Acrofan, the biotechnology company Clover Pharmaceuticals Inc. has recently announced that the first patient has been dosed in its phase 3 clinical study. This study…

Continue Reading A Biosimilar Drug for Treating Rheumatoid Arthritis and Ankylosing Spondylitis Begins Phase 3 Trials

A Blind Artist, A Motivational Speaker Who Can’t Talk, and a Single Mom with Rheumatoid Arthritis

  Since most people cannot truly understand the challenges faced by a blind person, then an artist who cannot see is unimaginable. According to a recent article in the British…

Continue Reading A Blind Artist, A Motivational Speaker Who Can’t Talk, and a Single Mom with Rheumatoid Arthritis
Biosimilar Drug for Ankylosing Spondylitis gets Approved by the FDA
stevepb / Pixabay

Biosimilar Drug for Ankylosing Spondylitis gets Approved by the FDA

According to a story from Ankylosing Spondylitis News, the drug Hadlima, which is a biosimilar to the drug Humira (adalimumab), was recently approved by the US Food and Drug Administration…

Continue Reading Biosimilar Drug for Ankylosing Spondylitis gets Approved by the FDA

ICYMI: A Good Business Decision vs. The Right Ethical Choice: Conducting Clinical Trials

A recent article written by Craig Klugman debates the ethical obligations pharmaceutical companies have to conduct clinical trials for drugs which have a likely potential to benefit a patient population…

Continue Reading ICYMI: A Good Business Decision vs. The Right Ethical Choice: Conducting Clinical Trials

Legal and Ethical Questions: What is Pharma’s Obligation to Pursue Development of a Promising but Non-Profitable Drug?

  Dr. Craig Klugman, a bioethics professor at DePaul University, expresses his opinion in this recent article in Columbia University’s Bioethics.com. Dr. Klugman begins with a discussion of Pfizer’s biological drug,…

Continue Reading Legal and Ethical Questions: What is Pharma’s Obligation to Pursue Development of a Promising but Non-Profitable Drug?

The FDA is Reversing Course on Unapproved Products Sold by Stem Cell Manufacturers

  The FDA’s “untitled letter” to R3 Stem Cell (R3), based in Scottsdale Arizona, cautioned R3 that the product they are marketing is considered a drug. It must, therefore, be…

Continue Reading The FDA is Reversing Course on Unapproved Products Sold by Stem Cell Manufacturers

Two Sisters with Rare Conditions Founded The Fighting H.A.R.D. Foundation to Help Other Patients Feel Less Alone

The Origins of Fighting H.A.R.D. The Fighting H.A.R.D. Foundation was established in 2015 by two sisters who both live with multiple rare diagnoses. 16-year-old Allie is diagnosed with juvenile rheumatoid…

Continue Reading Two Sisters with Rare Conditions Founded The Fighting H.A.R.D. Foundation to Help Other Patients Feel Less Alone

Extremely Positive Results from Systemic Juvenile Idiopathic Arthritis 5-year Follow-Up Study in the EU

Extremely positive results have just been announced from a 5-year follow-up study of a systemic juvenile idiopathic arthritis (sJIA) treatment called Kineret. This treatment has been approved for use in…

Continue Reading Extremely Positive Results from Systemic Juvenile Idiopathic Arthritis 5-year Follow-Up Study in the EU

How Changing to Outcome-Based Reimbursement Models is Better for Rare Disease Patients

Shifting Contracts Over the years the United States healthcare system has shifted more toward reimbursement models that are outcome-based instead of service-based. In essence, this means that instead of paying…

Continue Reading How Changing to Outcome-Based Reimbursement Models is Better for Rare Disease Patients
Can Direct-to-Consumer Genetic Testing Predict Rheumatological Diseases?
qimono / Pixabay

Can Direct-to-Consumer Genetic Testing Predict Rheumatological Diseases?

Genetic testing, such as 23andMe, has been approved by the FDA for direct-to-consumer genetic testing.  However, this type of testing has not been approved to predict rheumatic diseases. Research is…

Continue Reading Can Direct-to-Consumer Genetic Testing Predict Rheumatological Diseases?

New Potential Treatment for Systemic-Onset Juvenile Idiopathic Arthritis Investigated in China

SOJIA SOJIA stands for systemic-onset Juvenile Idiopathic Arthritis (JIV). It is a very severe form of JIA which causes joint pain, inflammation, recurrent fevers, and a skin rash. Patients often take predinsolone,…

Continue Reading New Potential Treatment for Systemic-Onset Juvenile Idiopathic Arthritis Investigated in China
New Approval Gives Juvenile Idiopathic Arthritis Patients More Options
kfuhlert / Pixabay

New Approval Gives Juvenile Idiopathic Arthritis Patients More Options

On November 26, 2018, the FDA approved a new autoinjector for individuals with severe rheumatoid arthritis (RA), giant cell arteritis, and polyarticular or systemic juvenile idiopathic arthritis (aged 2 and older). It's…

Continue Reading New Approval Gives Juvenile Idiopathic Arthritis Patients More Options
Let’s Come Together for World Autoimmune Arthritis Day!
Source: Pixabay

Let’s Come Together for World Autoimmune Arthritis Day!

Sunday, May 20th is World Autoimmune Arthritis Day! The global awareness day is aimed at raising money, consciousness, and solidarity for the millions of people who suffer from one of many arthritic…

Continue Reading Let’s Come Together for World Autoimmune Arthritis Day!
Anti-Inflammatory Effects of Baking Soda Could Help Fight Rheumatoid Arthritis and Chronic Kidney Disease
source: pixabay.com

Anti-Inflammatory Effects of Baking Soda Could Help Fight Rheumatoid Arthritis and Chronic Kidney Disease

According to a story from Healthline, a daily regimen of baking soda consumption could help reduce the severity of inflammation in certain diseases, such as chronic kidney disease and rheumatoid…

Continue Reading Anti-Inflammatory Effects of Baking Soda Could Help Fight Rheumatoid Arthritis and Chronic Kidney Disease
Maine Legislative Bill Challenges Step Therapy, Which Allows Insurers to Make Care Decisions
Source: Pixabay

Maine Legislative Bill Challenges Step Therapy, Which Allows Insurers to Make Care Decisions

Many medical insurers follow a practice known as step therapy. A new law presented to legislators in Maine proposes to protect patients from such practices. In her column for Central…

Continue Reading Maine Legislative Bill Challenges Step Therapy, Which Allows Insurers to Make Care Decisions